



The University of
Nottingham

UNITED KINGDOM · CHINA · MALAYSIA

Liu, Mengjie and Mountford, Simon J. and Richardson, Rachel R. and Groenen, Marleen and Holliday, Nicholas D. and Thompson, Philip E. (2016) Optically pure, structural and fluorescent analogues of a dimeric Y4 receptor agonist derived by an olefin metathesis approach. *Journal of Medicinal Chemistry* . ISSN 1520-4804

Access from the University of Nottingham repository:

<http://eprints.nottingham.ac.uk/34144/1/acs.jmedchem.6b00310.pdf>

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see:
http://eprints.nottingham.ac.uk/end_user_agreement.pdf

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk

Optically pure, structural and fluorescent analogues of a dimeric Y4 receptor agonist derived by an olefin metathesis approach.

Mengjie Liu, Simon J. Mountford, Rachel R. Richardson,
Marleen Groenen, Nicholas D. Holliday, and Philip E. Thompson

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.6b00310 • Publication Date (Web): 13 Jun 2016

Downloaded from <http://pubs.acs.org> on June 16, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3 **Optically pure, structural and fluorescent analogues of a dimeric**
4
5
6 **Y₄ receptor agonist derived by an olefin metathesis approach.**
7

8
9 Mengjie Liu,¹ Simon J. Mountford,¹ Rachel R. Richardson,² Marleen Groenen,² Nicholas D.
10
11 Holliday,² Philip E. Thompson.^{1*}
12

13 *¹Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences. 381 Royal Parade,*
14
15 *Parkville, VIC 3052, Australia.*
16

17
18
19 *²School of Life Sciences, University of Nottingham, Queen's Medical Centre. Derby Road,*
20
21 *Nottingham NG7 2UH, United Kingdom.*
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

The dimeric peptide **1** (BVD-74D, as a diastereomeric mixture) is a potent and selective Neuropeptide Y Y₄ receptor agonist. It represents a valuable candidate in developing traceable ligands for pharmacological studies of Y₄ receptors, and as a lead compound for anti-obesity drugs. Its optically pure stereoisomers along with analogues and fluorescently labelled variants were prepared by exploiting alkene metathesis reactions. The (2*R*,7*R*)-diaminosuberoyl containing peptide, (*R,R*)-**1** had markedly higher affinity and agonist efficacy than its (*S,S*)-counterpart. Furthermore the sulfo-Cy5 labelled (*R,R*)-**14** retained high agonist potency as a novel fluorescent ligand for imaging Y₄ receptors.


Introduction

The physiological functions of three polypeptides that form the NPY peptide family, neuropeptide Y (NPY)¹ and peptide YY (PYY),² and pancreatic polypeptide (PP),³ are mediated by Y receptors, where four subtypes have been identified in human: Y₁R, Y₂R, Y₄R and Y₅R. All subtypes belong to the rhodopsin-like G_i coupled G-protein coupled receptor (GPCR) superfamily.⁴ These Y receptor subtypes exhibit different binding affinity to the three members of NPY peptide family. It was found that Y₁R and Y₂R exhibit similar affinity to NPY and PYY, but poor affinity to PP. Y₄R is a PP-selective subtype with lower affinity for NPY and PYY. Lastly, all three peptides are equally potent at Y₅R.⁵

Activation of the PP/Y₄R signalling system induces satiety and promotes energy expenditure. This suggests that Y₄R agonists may become clinically useful anti-obesity drugs, while Y₄R antagonists may have potential as orexigenic agents to treat anorexia.⁶⁻⁹ In developing such ligands, truncated peptide analogues are becoming increasingly popular. For example, [Nle³⁰]hPP₂₅₋₃₆ and [Leu³⁴]pNPY₂₅₋₃₆ were found to be Y₄R selective partial agonists,¹⁰ and a nonapeptide based on the C-terminal fragment of NPY, Ile-Asn-Pro-Ile-Tyr-Arg-Leu-Arg-Tyr-NH₂ exhibits moderate Y₄R agonism and Y₁R competitive antagonism with similar potency.¹¹⁻¹³ Its lactam-bridged dimeric variant *bis*(29/31', 29/31')[(Glu²⁹, Pro³⁰, Dpa³¹, Tyr³², Leu³⁴)NPY₂₈₋₃₆], also known as 1229U91, showed enhanced potency at both receptor subtypes but is in particular the most potent known Y₁R antagonist.¹³⁻¹⁷

Another of several highly potent Y receptor ligands based upon dimeric C-terminal sequences is D/L-2,7-diaminooctanedioyl-bis(YRLRY-NH₂), **1** (BVD-74D)¹⁸ (Figure 1). This peptide exhibited comparable Y₄R affinity with the native hPP (K_i = 0.05 nM vs. 0.08 nM) and showed 150-fold selectivity for Y₄R over Y₁R, and negligible affinity to Y₂R and Y₅R. In fasted rat subjects, **1** showed equally potent inhibitory effects on food intake as the endogenous PP.¹⁸ A later study also reported that **1** significantly reduced food intake, water

intake and weight gain in mice fed with normal and high-fat diet.¹⁹ However, the reported compound is, in fact, a mixture of diastereomers composed of the (2*S*,7*S*)- and (2*R*,7*R*)-diaminooctanedioyl-containing stereoisomers,¹⁸ and they are inseparable by RP-HPLC. Therefore it was unclear which stereoisomer contributed to the *in vitro* and *in vivo* pharmacological activity.



1 (BVD-74D)

Figure 1: The BVD-74D peptide **1** reported by Balasubramaniam *et al.* is a diastereomeric mixture of the (2*S*,7*S*)- and (2*R*,7*R*)-diaminooctanedioyl stereoisomers.

We aimed to resolve this issue, and set a platform for the broader investigation of Y₄R pharmacology by the synthesis of optically pure stereoisomers of **1** and related analogues that probe the role of the bridging group and the role of the dimeric structure in facilitating high affinity. We hereby present our work on synthesis of a series of optically pure analogues of (*S,S*)-**1** and (*R,R*)-**1** along with their fluorescently labelled variants. We developed methodology for preparing the dimeric peptides utilising Grubbs metathesis, either in the synthesis of optically pure 2,7-diaminosuberic acid building blocks or the on resin metathesis of monomeric precursor peptides.²⁰⁻²² Those peptide analogues were analysed using cell based Y₄R competition binding assays and β-arrestin recruitment assays to identify the (*R,R*)-diastereomers as the high affinity constituent of **1** and the corresponding fluorescent analogues.


Results and Discussion

Chemistry

The main challenge in developing a convenient and robust strategy for synthesising optically pure dimeric **1** analogues was to identify an optimal condition for metathesis reactions. Two different approaches were attempted. The first approach involved pre-synthesis of the 2,7-diaminosuberic acid unit then bis-coupling to the linear peptidyl-resin, while the second involved a solid phase cross-metathesis between two completed linear N-terminal allylglycine containing peptides.

Synthesis of (*S,S*)-**1** and (*R,R*)-**1**


The synthesis of (*2S,7S*)-*N,N*-di-Boc-diaminosuberic acid²³ (*2S,7S*)-**5** via metathesis was achieved by adapting the methods of Nolen *et al.*²⁴ and Ward *et al.*²⁵ (Scheme 1) The (*S*)-*N*-Boc-allylglycine methyl ester (**2**) was treated with Grubbs catalyst 2nd generation in refluxing DCM overnight to obtain the desired alkene **3** in 95% yield. The intermediate **3** was then hydrogenated in presence of 10% Pd/C, which gave **4** almost quantitatively. Finally, the desired product (*2S,7S*)-**5** was generated by ester hydrolysis. Spectroscopic data for (*2S,7S*)-**5** were consistent with that previously reported,²³ including the determined (-) optical rotation in DMF.²⁶ Experimental details are provided in Supporting Information.



Scheme 1: Synthesis of (*2S,7S*)-*N,N*-di-Boc-diaminosuberic acid (*2S,7S*)-**5**. Reagents and conditions: a. Grubbs catalyst 2nd generation, DCM, reflux, overnight, 95%; b. 10% Pd/C, MeOH, H₂, RT, overnight; c. NaOH in H₂O (6 mg/ml), MeOH, reflux, overnight, 50% (from **3**).

To prepare the (*2R,7R*)-*N,N*-di-Boc-diaminosuberic acid, (*2R,7R*)-**5**, we investigated the use of 1,3-benzenedimethanol as a “template” to enable selective ring-closure metathesis as


reported by previously.^{27, 28} Esterification of Boc-D-allylglycine-OH (**6**) gave the diester **7** which was a substrate for RCM, and gave **8** in 54% yield. Finally one-pot reduction and hydrogenolysis of **8** was achieved by treating with hydrogen in the presence of 10% Pd/C affording (2*R*,7*R*)-**5**. Polarimetry confirmed the expected (+) optical rotation of the precursor.²⁶



Scheme 2: Synthesis of (2*R*,7*R*)-*N,N*-di-Boc-diaminosuberic acid, (2*R*,7*R*)-**5**. Reagents and conditions: a. benzenedimethanol, EDCI, DMAP, DCM, RT, overnight, 56%; b. Grubbs catalyst 2nd generation, DCM, N₂, reflux, overnight, 54%; c. 10% Pd/C, MeOH, 1 atm H₂, 53%.

To further confirm the chiral integrity of the products, a chiral HPLC method was developed that showed that preparation of (2*S*,7*S*)-**5** and (2*R*,7*R*)-**5** was not accompanied by significant racemization either to each other or to the meso (2*R*,7*S*)-**5**²⁹ in these syntheses (see Supporting Information).


Having the protected building blocks in hand, dimeric peptide analogues (*S,S*)-**1** and (*R,R*)-**1** were prepared by conventional solid phase peptide synthesis (Scheme 3). After constructing the linear peptide chain on Rink amide resin, the coupling was carried out using 0.5 equivalents of the Boc-protected 2,7-diaminosuberic acid (*S,S*)-**5** or (*R,R*)-**5** activated with PyClock and overnight incubation. After cleavage, the desired peptides were obtained and readily purified by RP-HPLC.



Scheme 3: Synthesis of *(S,S)*-**1** using pre-synthesised *(2S,7S)*-*N,N*-di-Boc-diaminosuberic acid **5**. Reagents and conditions: a. *(2S,7S)*-**5**, PyClock, DIPEA, DMF, RT, overnight; b. Reagent K, RT, 3 h.

As an alternative approach, the synthesis of dimeric peptides was achieved by solid phase cross-metathesis of the corresponding resin-bound protected allylglycine containing peptides. (Scheme 4) The monomeric peptide chain containing either L- or D-allylglycine was first assembled following the standard Fmoc-based solid phase synthesis strategy, where the N-terminal Fmoc group was retained. The peptidyl-resin was then subject to cross-metathesis by treating with Grubbs catalyst 2nd generation under deoxygenated conditions and microwave heating in presence of LiCl as a chaotropic salt.²¹ Fmoc deprotection followed by cleavage yielded the alkenyl peptides, *(S,S)*-**9** and *(R,R)*-**9**.

The synthesis of *(R,R)*-**1** was also achieved by hydrogenation of *(R,R)*-**9** in presence of 10% Pd/C in EtOAc (Scheme 4). While successful and operationally straightforward, the yield and purity of the crude peptide product was not as good as the same peptide made from pre-synthesised diaminosuberic acids as described above.



Scheme 4: Synthesis of dimeric peptides (R,R) -**9** and (R,R) -**1** via solid phase metathesis reaction. Reagents and conditions: a. Grubbs catalyst 2nd generation, LiCl in DMF, DCM, μ wave 100°C, 3 h; b. piperidine (20%) in DMF, RT, 5 min \times 2; c. Reagent K, RT, 3 h; d. Pd/C cartridge, H₂ (50 psi), EtOAc, 50°C, 1 h.


Synthesis of homo- and hetero-dimeric methyl esters of (S,S) -**1**

Having established efficient strategies for preparation of dimeric analogues with specified stereo-configuration, we investigated the role of the C-terminal amides in Y₄R interaction by replacing them as mono- or di-methyl esters. Our strategy was to utilise side-chain anchoring to the resin to allow manipulation of the terminal carboxylate. Peptide anchoring to resin via the side-chain of tyrosine esters has been described on both benzyl-type resins³⁰ and 2-chlorotrityl chloride resin.³¹

We first prepared the free phenolic tyrosine derivatives, Fmoc-Tyr-OMe (**10**)³² and Fmoc-Tyr amide (**11**)³³ (see Supporting Information). The di-methyl ester (S,S) -**12** was achieved by coupling **10** to 2-chlorotrityl chloride resin via the phenol group.³¹ The remainder of the peptide sequence was assembled as described above with final coupling of $(2S,7S)$ -**5** and standard acidolytic cleavage (Scheme 5).

To synthesise the heterodimeric mono-methyl ester (S,S) -**13**, **10** and **11** were anchored simultaneously to 2-chlorotrityl chloride resin as a 1:1 mixture. Standard SPPS was continued as described above and final coupling of $(2S,7S)$ -**5** was followed by standard cleavage. The products were an approximately 2:1:1 mixture of the desired heterodimer (S,S) -**13** and the homodimers, the di-amide (S,S) -**1** and di-methyl ester (S,S) -**12** (Scheme 5). The three major

peptide products were readily resolved by RP-HPLC allowing isolation of the desired product. Notable in the syntheses of compounds (*S,S*)-**12** and (*S,S*)-**13** was an excellent recovery of peptide products, indicative of more efficient cleavage from the 2-chlorotrityl chloride resin than from Rink Amide resin.



Scheme 5: Synthesis of peptides (*S,S*)-**12** and (*S,S*)-**13**. Reagents and conditions: a. 2-chlorotrityl chloride resin, DIPEA, DCM, RT, overnight; b. standard solid phase synthesis; c. **5**, PyClock, DIPEA, DMF, RT, overnight; d. Reagent K, RT, 3 h.

Synthesis of fluorescently labelled diastereomers of (*S,S*)-**1** and (*R,R*)-**1**

In order to develop fluorescently labelled Y₄R-targeting ligands for *in vitro* Y₄R studies, (*S,S*)-**1**, (*R,R*)-**1**, (*S,S*)-**II** and (*R,R*)-**II** were conjugated with either a rhodamine B (RhB) derivative³⁴ or the commercially available sulfo-Cy5 (sCy5) dye (Figure 2). Following our previously reported methods for mono-conjugation of dimeric peptides,³⁵ peptides (*S,S*)-**1** and (*R,R*)-**1** were treated with 0.7 molar equivalents of sCy5 in presence of PyClock and DIPEA to give the desired mono-labelled analogues (*S,S*)-**14** and (*R,R*)-**14** respectively after purification, and peptides (*S,S*)-**1**, (*S,S*)-**9** and (*R,R*)-**9** treated with the rhodamine B derivative to give (*S,S*)-**15**, (*S,S*)-**16** and (*R,R*)-**16** respectively (Scheme 6).





Figure 2: The structures of carboxy derivatised fluorophore reagents used: sulfo-Cy5 (sCy5) and rhodamine B (RhB).



Scheme 6: Example of fluorophore conjugation of (S,S) -1. Reagents and condition: sCy5 or RhB (0.7 eq.), PyClock, DIPEA in DMF, RT, overnight.

In summary, we have successfully developed unambiguous synthetic routes to prepare optically pure **1** and analogues through both solution and solid phase alkene metathesis reactions. Mono-labelled fluorescent analogues were conveniently prepared by standard solution phase coupling using limited molar equivalents of fluorophores. Utilising these strategies, 11 dimeric analogues were prepared and their analytical data are summarised in Table 1.

Table 1: Synthesised dimeric peptides and their analytical data.

Code	Sequence ^a	ESI-MS ^b	HPLC RT. ^c (min)
(S,S) -1	(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-NH ₂) ₂	569.75	11.21

(R,R)-1	(2 <i>R</i> ,7 <i>R</i>)-sub(YRLRY-NH ₂) ₂	569.85	11.16
(S,S)-9	(2 <i>S</i> ,7 <i>S</i>)-Δsub(YRLRY-NH ₂) ₂	569.05	11.19
(R,R)-9	(2 <i>R</i> ,7 <i>R</i>)-Δsub(YRLRY-NH ₂) ₂	569.10	11.34
(S,S)-12	(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-OMe) ₂	579.85	12.06
(S,S)-13	(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-NH ₂)(YRLRY-OMe)	574.85	11.61
(S,S)-14	mono-sCy5-(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-NH ₂) ₂	782.70	12.38
(R,R)-14	mono-sCy5-(2 <i>R</i> ,7 <i>R</i>)-sub(YRLRY-NH ₂) ₂	782.75	12.36
(S,S)-15	monoRhB-(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-NH ₂)	767.40	13.37
(S,S)-16	monoRhB-(2 <i>S</i> ,7 <i>S</i>)-Δsub(YRLRY-NH ₂) ₂	766.65	13.36
(R,R)-16	monoRhB-(2 <i>R</i> ,7 <i>R</i>)-Δsub(YRLRY-NH ₂) ₂	766.70	13.26

- a. Sub = 2,7-diaminosuberoyl linkage; Δsub = 2,7-diaminooctene-4-dioyl linkage.
- b. ESI-MS base peak corresponds to [M+3H]³⁺.
- c. HPLC retention time using a Phenomenex Luna C-8 column (100Å, 3μm, 100×2.00mm). The gradient is composed of 100% H₂O (0.1% TFA) for 4 min, 0-60% acetonitrile in H₂O (0.1% TFA) over 10 min, and isocratic 60% acetonitrile in H₂O (0.1% TFA) for 1 min.

Pharmacology

The pharmacological characteristics of these dimeric peptides were assessed by receptor binding and functional assays using whole cell assay systems. This enabled binding to be assessed in physiological buffer in cells (expressing human Y₄R tagged with green fluorescent protein, GFP) rather than membranes, to provide equivalence with subsequent functional measurements.

Y₄R binding affinity data were obtained by competition binding against the sCy5-labelled peptide **17**, ([Lys²(sCy5),Arg⁴]BVD-15, 100 nM), analysed on a high content imaging plate reader (Table 2, Figure 3).^{36, 37} The endogenous reference ligand, human PP, showed

nanomolar affinity ($IC_{50} = 2.31$ nM) in this assay. Of all the peptides, (2*R*,7*R*)-**1** exhibited the highest Y_4R affinity ($IC_{50} = 12.7$ nM), and was 5.5-fold higher in affinity than (2*S*,7*S*)-**1**.

Table 2: Synthesised dimeric peptides and their pharmacological data.

Code	Sequence ^a	pIC_{50} ^b	R_{max} ^c (%) 100 nM PP)	pEC_{50} ^d
PP		8.64±0.12	96.3±4.0	8.58±0.10
(<i>S,S</i>)- 1	(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-NH ₂) ₂	7.16±0.10	57.1±10.9	7.08±0.30
(<i>R,R</i>)- 1	(2 <i>R</i> ,7 <i>R</i>)-sub(YRLRY-NH ₂) ₂	7.90±0.10	61.5±0.17	8.33±0.17
(<i>S,S</i>)- 9	(2 <i>S</i> ,7 <i>S</i>)- Δ sub(YRLRY-NH ₂) ₂	6.88±0.09	44.5±4.8	7.52±0.20
(<i>R,R</i>)- 9	(2 <i>R</i> ,7 <i>R</i>)- Δ sub(YRLRY-NH ₂) ₂	7.62±0.11	61.0±5.2	7.42±0.15
(<i>S,S</i>)- 12	(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-OMe) ₂	6.21±0.11	11.3±6.7 ^d	N.D.
(<i>S,S</i>)- 13	(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-NH ₂)(YRLRY-OMe)	7.03±0.10	49.1±6.8	<6.5
(<i>S,S</i>)- 14	mono-sCy5-(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-NH ₂) ₂	N.D.	56.6±11.8	7.02±0.33
(<i>R,R</i>)- 14	mono-sCy5-(2 <i>R</i> ,7 <i>R</i>)-sub(YRLRY-NH ₂) ₂	N.D.	65.6±5.7	7.48±0.16
(<i>S,S</i>)- 15	monoRhB-(2 <i>S</i> ,7 <i>S</i>)-sub(YRLRY-NH ₂)	7.15±0.09	15.9±9.1 ^d	N.D.
(<i>S,S</i>)- 16	monoRhB-(2 <i>S</i> ,7 <i>S</i>)- Δ sub(YRLRY-NH ₂) ₂	7.16±0.10	29.2±4.6	8.26±0.37
(<i>R,R</i>)- 16	monoRhB-(2 <i>R</i> ,7 <i>R</i>)- Δ sub(YRLRY-NH ₂) ₂	7.15±0.09	39.3±4.2	8.43±0.26

a. Sub = 2,7-diaminosuberoyl linkage; Δ sub = 2,7-diaminooctene-4-dioyl linkage

b. Derived from competition binding assays using 100 nM **17** as the fluorescent ligand.

c. From Y_4R - β -arrestin2 recruitment assays.

d. In the absence of significant agonist activity, the effect at 1 μ M peptide is reported. N.D.

= not determined

The remaining analogues examined here have not been previously described (Table 2). In the alkenyl dimer series, a preference for the (*R,R*)-**9** was again observed compared to the (*S,S*)-diastereomer, but overall these compounds showed 2- to 3-fold lower affinity for Y_4R than

1
2
3 the corresponding diaminosuberic linked analogues **1**. It can be concluded that
4
5 conformational restraint due to the presence of the alkene group is not favoured. Substitution
6
7 of one C-terminal amide (*S,S*)-**13** for an ester moiety did not lead to a major loss of Y₄R
8
9 affinity compared to the corresponding diamide (*S,S*)-**1** in these assays. However,
10
11 replacement of both amides as in compound (*S,S*)-**12**, has a major impact with an order of
12
13 magnitude drop in affinity. Mono *N*-terminal modification of (*R,R*)-**9** with rhodamine B
14
15 giving (*R,R*)-**16** led to a 3-fold reduction in affinity, but rhodamine B addition was well
16
17 tolerated in analogues (*S,S*)-**15** and (*S,S*)-**16**. The three rhodamine B containing peptides had
18
19 essentially overlapping competition curves.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: Y₄R competition binding assays using high content imaging. A. 293TR Y₄-GFP cells were incubated with 100 nM, **17** in the absence (control) or presence of increasing concentrations of stereoisomers of **1**. Following 30 min at 37°C, Y₄-GFP and fluorescent

1
2
3 ligand images were acquired on an IX Ultra plater reader. The panels show 400×400 regions of
4
5 interest from the 1000×1000 pixel original plate images; scale bar 50 μm. B. Specific binding
6
7 of **17** was quantified and normalised using granularity analysis as described in the methods,
8
9 to obtain competition curves for peptide analogues synthesised in the current study. Graphs
10
11 show pooled competition data (n = 5), from which the pIC₅₀ values in Table 2 were
12
13 determined.

14
15
16 The selectivity of representative peptides (*R,R*)-**1**, (*S,S*)-**9** and (*S,S*)-**12** was measured by
17
18 Y₁R-GFP whole cell competition binding (using the same fluorescent ligand **17** (10 nM), and
19
20 confirmed at least 30-fold selectivity of representative for Y₄R over Y₁R, the Y receptor
21
22 subtype most closely related in amino acid homology.³⁸ Y₁R pIC₅₀ values were 6.44±0.14,
23
24 6.31±0.30 and 6.63±0.12 for analogues (*R,R*)-**1**, (*S,S*)-**9** and (*S,S*)-**12** respectively (n = 3).

25
26
27 The functional Y₄R agonism produced by the peptides was analysed using a β-arrestin2
28
29 recruitment assay to detect Y₄R activation (Figure 4), as previously described.^{39, 40} One
30
31 advantage of this assay is its limited receptor reserve, which improves correspondence
32
33 between agonist potency (as EC₅₀, the concentration of agonist that produces 50% of its
34
35 maximal response) and underlying functional receptor affinities, and also the likelihood that
36
37 differences in agonist intrinsic efficacy are revealed through changes in relative maximum
38
39 response (R_{max}).⁴¹ Thus the reference agonist human PP stimulated β-arrestin2 association
40
41 with an EC₅₀ value (2.6 nM) very similar to its derived pIC₅₀ in the whole cell Y₄R binding
42
43 experiments.
44
45

46
47 Compared to PP, all the peptides were partial agonists in the Y₄R-arrestin recruitment assays,
48
49 with typical R_{max} values 44-62% of that of PP (Table 2). The order of potency broadly
50
51 reflected binding data in that (i) (*R,R*)-**1** (EC₅₀ = 4.6 nM) was 20-fold more potent than the
52
53 (*S,S*)-**1**, (Figure 4A), (ii) the alkenyl derivatives (*R,R*)-**9** and (*S,S*)-**9** were less potent overall
54
55 than the dimers with saturated linkages (Figure 4B) and (iii) replacement of one or both C-
56
57
58
59
60

terminal amides with ester moieties, (*S,S*)-**13** and (*S,S*)-**12** respectively, resulted in a loss of potency and efficacy (Figure 4B).

The functional assay enabled assessment of both RhB- and sCy5-labelled analogues as Y₄R agonists. In general, maximum responses to rhodamine analogues were reduced compared to the respective parent compounds, with compound (*S,S*)-**15** (RhB derivative of (*S,S*)-**1**) being without significant effect in the assay (Table 2). In contrast, mono-labelling with sCy5 as in (*S,S*)-**14** and (*R,R*)-**14**, preserved the same level of maximal response exhibited by their parent peptides (Figure 4C). The sCy5-labelled (*R,R*)-**14** was more potent, with an EC₅₀ value (34 nM) approximately 7-fold lower potency than (*R,R*)-**1**.





Figure 4: Y₄R agonism as assessed in the Y₄R β-arrestin2 recruitment assay. The HEK293 Y₄ β-arrestin2 BiFC cell line was stimulated for 60 min with human PP or synthesised compounds, and the development of complemented YFP fluorescence following Y₄R activation was imaged and quantified using granularity analysis. Panels A-C represent pooled data (n = 4 or greater), normalised to the 100 nM PP response, from which pEC₅₀ and R_{max} values were estimated (Table 2).

The sCy5 derivatives (*S,S*)-**14** and (*R,R*)-**14** were explored further for their properties as novel Y₄R fluorescent ligands. Both compounds labelled Y₄R-GFP expressing 293TR cells in a concentration dependent manner (with (*R,R*)-**14** more potent), dependent on prior induction of receptor expression via tetracycline pretreatment (Figure 5). As anticipated for a ligand with agonist properties, both surface and intracellular distribution of sCy5 fluorescence was

1
2
3 observed, likely reflecting some co-internalisation of Y₄R ligand complexes from the plasma
4 membrane following receptor activation. The presence of increasing concentrations of PP
5 competed for the binding of (*S,S*)-**14** or (*R,R*)-**14**.
6
7

8
9 To confirm the utility of (*R,R*)-**14** in competition binding experiments, the fluorescence
10 spectrum in physiological buffers was determined and found the lambda max to be the same
11 as that of the underivatised sCy5-NHS dye (absorption max 656 nm, emission max 665 nm)
12 with a relative quantum yield of 31% (see Supporting Information). We then used (*R,R*)-**14** to
13 label cells with 100 nM (*R,R*)-**14**, and determined the PP pIC₅₀ was 8.36±0.09 (IC₅₀ = 4.31
14 nM, n = 3), consistent with the IC₅₀ obtained using **17** (see Table 2).
15
16

17
18 The collected assay data from these studies raise interesting questions regarding the
19 molecular mechanism governing the high potency of peptide (*R,R*)-**1** as compared to other
20 analogues, and therefore how dimeric analogues impart enhanced affinity generally. Set
21 against recent studies of the Y₄R-hPP interaction,⁴² the simplest model is that the “first arm”
22 of the dimer binds the receptor in the canonical fashion while the “second arm” contributes to
23 the affinity, perhaps by mimicry of the hPP helical region 14-30. An alternate view might be
24 that the ligand binding is driven by the doubling of the local concentration of the C-terminal
25 binding motif. The influence of the flexible bridging ligand argues against this latter
26 explanation although the clear preference for the presence of the (*R,R*)-configuration may
27 imply a preference for a D-amino acid at that position of the truncated peptide that has not
28 been tested in other analogues. The comparable affinity of (*S,S*)-**1** and the half ester, half
29 amide (*S,S*)-**13** may also suggest that the two arms play different roles in receptor binding,
30 where in the “second arm” the C-terminal carboxamide is not so critical. The development of
31 synthetic routes to further interrogate the structure-activity of stereochemically defined
32 homo- and heterodimers suggests a great opportunity for the much needed development of
33 Y₄R ligands.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Figure 5:** sCy5 labelled peptides as fluorescent Y₄R ligands. Representative images show
4 binding and localisation of mono-sCy5 labelled (*S,S*)-**14** (300 nM) or (*R,R*)-**14** (100 nM)
5 following 30 min pre-incubation with 293TR Y₄GFP cells. Panels illustrate the lack of
6 fluorescent ligand binding in controls cells without Y₄R protein expression induced by
7 tetracycline treatment (No Tet), or in the presence of competing ligand (1 μM PP). Examples
8 are magnified regions of individual IX Ultra images, as described for **Figure 4**, representative
9 of 3 independent experiments. Scale bar 50 μm.
10
11
12
13
14
15
16
17

18 **Conclusion**

19
20 Pharmacological observations support the conclusion that the (*R,R*)-**1** is the active principle
21 of the original mixture of diastereomers **1**, and as for the native peptides, C-terminal
22 amidation of these compounds is required for Y₄R agonist activity. As previous fluorescent
23 ligand SAR studies have indicated,^{43, 44} the choice of rhodamine or sCy5 fluorophore
24 influences the result Y₄R properties of the labelled compounds, with mono-sCy5 labelled
25 derivative (*R,R*)-**14** being identified as a novel nanomolar affinity fluorescent Y₄R agonist.
26
27
28
29
30
31
32
33

34 **Experimental Section**

35 **Materials**

36
37 N^α-Fmoc and N^α-Boc protected amino acids were purchased from Auspep, Chemimpex and
38 Mimotopes. Unless otherwise specified, all amino acids used were of L-conformation. Rink
39 amide resin (0.53 meq/g, 100-200 mesh), 2-chlorotrityl chloride resin (1.12 meq/g, 200-400
40 mesh), HCTU and PyClock were obtained from Chemimpex. TFA was purchased from Alfa
41 Aesar. Thioanisole, 1,2-ethanedithiol, DIPEA, piperidine, Boc anhydride, triethylamine,
42 EDCI, DMAP, 1,3-benzenedimethanol, Fmoc-OSu, pyridine, 1,4-dioxane and Grubbs
43 catalyst 2nd generation were purchased from Sigma-Aldrich. Phenol, chlorotrimethylsilane
44 and all solvents were obtained from Merck. The sCy5 fluorescence probe was purchased
45 from W&J PharmaChem. The Rhodamine B analogue was purchased from Sigma-Aldrich
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and modified as reported.³⁴ All solvents were of analytical grade, and all chemicals were used
4
5 without further purification.
6

7
8 Molecular mass of the compounds were determined by ESI-MS using a Shimadzu
9
10 LCMS2020 instrument, incorporating a Phenomenex Luna C-8 column (100Å, 3µm,
11
12 100×2.00mm). This system used 0.05% TFA in MilliQ water as the aqueous buffer, and
13
14 0.05% TFA in acetonitrile as the organic buffer. The eluting profile was a linear gradient of
15
16 0-60% acetonitrile in water over 10 min at 0.2 ml/min.
17

18
19 HRMS analyses were carried out on an Agilent 6224 TOF LC/MS Mass Spectrometer
20
21 coupled to an Agilent 1290 Infinity (Agilent, Palo Alto, CA). All data were acquired and
22
23 reference mass corrected via a dual-spray electrospray ionisation (ESI) source. Acquisition
24
25 was performed using the Agilent Mass Hunter Data Acquisition software version B.05.00
26
27 Build 5.0.5042.2 and analysis was performed using Mass Hunter Qualitative Analysis version
28
29 B.05.00 Build 5.0.519.13.
30

31
32 Crude peptides were purified on a Phenomenex Luna C-8 column (100Å, 10µm,
33
34 250×21.2mm) utilising a Waters 600 semi-preparative RP-HPLC that incorporates a Waters
35
36 486 UV detector. The wavelength was set at 230 nm. This system used 0.1% TFA in MilliQ
37
38 water as the aqueous buffer, and 0.1% TFA in acetonitrile as the organic buffer. The eluting
39
40 profile was a linear gradient of 0-80% acetonitrile in water over 60 min at 10 ml/min.
41
42

43 **Peptide synthesis**

44
45 The purity of all reported peptides are $\geq 95\%$ according to the HPLC chromatographs
46
47 produced by the ESI-MS method described above.
48

49 **General synthesis**

50
51
52 Linear peptide chains were synthesised on Rink amide resin or 2-chlorotrityl chloride resin
53
54 (sequence dependent) using a 3-channel serial automated peptide synthesiser (“PS3”, Protein
55
56 Technologies Inc.), which adopted standard Fmoc-based solid phase synthesis strategy. Fmoc
57
58
59
60

deprotection was performed by 20% v/v piperidine in DMF for 2×5 min. Fmoc protected amino acids (3 eq.) were coupled using DMF as solvent, and DIPEA in DMF (7% v/v) with HCTU (3 eq.) as the activating agent for 50 min.

Protected peptide-resins were cleaved by treating with Reagent K (5 ml) composed of TFA-H₂O-thioanisole-phenol-EDT (82.5%:5%:5%:5%:2.5%) for 3 h. The cleavage mixture was filtered, concentrated by a stream of N₂, precipitated in cold Et₂O and centrifuged at 3000 rpm for 5 min. The crude product was dissolved in water-acetonitrile mixture (50%:50%) and lyophilised.

(2*S*,7*S*)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*S,S*)-1)

The linear peptide chain was prepared by the general method described above on Rink resin (0.05 meq). The peptide resin was treated with (2*S*,7*S*)-*N,N*-di-Boc-diaminosuberic acid, (*S,S*)-5 (10.0 mg, 0.5 eq.), PyClock (110 mg, 4 eq.), DIPEA (87.0 μl, 10 eq.) in DMF (5 ml) overnight. After cleavage and purification, the peptide was lyophilized to yield a white fluffy solid (3.5 mg). HPLC RT 11.21 min. ESI-MS: 569.75 (M+3H)³⁺. HRMS (ESI) m/z calculated for [C₈₀H₁₂₄N₂₆O₁₆+2H]²⁺, 853.4923, found: 853.4947.

(2*R*,7*R*)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*R,R*)-1)

The (*R,R*) diastereomer of **I** was prepared in the same fashion as the (*S,S*)-diastereomer, but on 0.05 mmol scale, and using (*R,R*)-5 yielding a fluffy white solid (13.4 mg). HPLC RT 11.16 min. ESI-MS: 569.85 (M+3H)³⁺. HRMS (ESI) m/z calculated for [C₈₀H₁₂₄N₂₆O₁₆+3H]³⁺ 569.6660, found: 569.6683.

Alternatively, peptide (*R,R*)-9 (16 mg) (see below) was dissolved in EtOAc (10 ml) then cycled through an H-Cube™ incorporating a 10% Pd/C cartridge at 50°C at 1.5 ml/min under H₂ (50 psi). After 1h the solvent was removed *in vacuo* and the residue was purified by HPLC to yield a white fluffy solid (9.2 mg).

(2*S*,7*S*)-Diaminooct-4-enedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*S,S*)-9)

1
2
3 The Fmoc protected linear peptide, Fmoc-Gly(All)-Tyr(OtBu)-Arg(Pbf)-Leu-Arg(Pbf)-
4 Tyr(OtBu)-Rink amide resin was treated with LiCl in DMF (4.2 mg/ml, 200 μ l), Grubbs
5 catalyst 2nd generation (0.2 *eq.*) and DCM (4.5 ml) in a glass microwave vessel. The mixture
6 was charged with N₂ and heated in a microwave reactor at 100°C for 3 h. After the solvent
7 was removed by filtration, Fmoc deprotection was performed using 20% v/v piperidine in
8 DMF (5 ml) for 2 \times 5 min, and the peptide was cleaved off resin as described above, to yield a
9 white fluffy solid (10.0 mg), HPLC RT 11.19 min. ESI-MS: 569.05 (M+3H)³⁺. HRMS (ESI)
10 m/z calculated for [C₈₀H₁₂₂N₂₆O₁₆+2H]²⁺ 852.9881.

21 **(2*R*,7*R*)-Diaminooct-4-enediol-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*R*,*R*)-9)**

22 The peptide was prepared as for (*S*,*S*)-9 above, but utilizing Fmoc-D-Gly(All) to yield a white
23 fluffy solid (5.1 mg), HPLC RT 11.34 min. ESI-MS: 569.10 (M+3H)³⁺.

27 **(2*S*,7*S*)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr dimethyl ester) ((*S*,*S*)-12)**

28 A mixture of Fmoc-Tyr-OMe, **10** (2 *eq.*) and DIPEA (6 *eq.*) in DCM (5 ml) was added to 2-
29 chlorotriyl resin and agitated overnight. The resin was filtered, washed with DCM \times 3,
30 MeOH \times 1 and Et₂O \times 1, and dried *in vacuo*. The derivatised resin was subject to standard solid
31 phase synthesis as described above and treated with (*S*,*S*)-5 as described for (*S*,*S*)-1 above.
32 After cleavage and purification, the peptide was lyophilized to yield a white fluffy solid (40.5
33 mg). HPLC RT 12.06 min. ESI-MS: 579.85 (M+3H)³⁺. HRMS (ESI) m/z calculated for
34 [C₈₂H₁₂₆N₂₄O₁₈+2H]²⁺ 868.4914, found: 868.4956.

45 **(2*S*,7*S*)-Diaminooctanedioyl-(Tyr-Arg-Leu-Arg-Tyr methyl ester) (Tyr-Arg-Leu-Arg-Tyr
46 amide) ((*S*,*S*)-13)**

47 (*S*,*S*)-13 was prepared as for (*S*,*S*)-12 above, except that the 2-chlorotriyl chloride resin was
48 treated with a 50%:50% mixture of Fmoc-Tyr-OMe (**10**) and Fmoc-Tyr-NH₂ (**11**). After
49 cleavage and purification, the peptide was lyophilized to yield a white fluffy solid (7.5 mg).
50 HPLC RT 11.61 min. ESI-MS: 574.85 (M+3H)³⁺. Side products of (*S*,*S*)-1 and (*S*,*S*)-12 were
51
52
53
54
55
56
57
58
59
60

also identified in the product mixture. HRMS (ESI) m/z calculated for $[C_{81}H_{125}N_{25}O_{17}+2H]^{2+}$ 860.9920 found: 860.9956.

Fluorescent labelling of peptides

Peptides were treated with a mixture of the labelling agent (sCy5 or RhB, see Figure 2) (0.7 eq.), PyClock (2 eq.) and NMM (12 eq.) in DMF (2 ml). The mixture was stirred in darkness overnight and DMF was removed *in vacuo*. The crude product was washed with TFA (1 ml), precipitated with cold Et₂O and centrifuged at 3000 rpm for 5 min. The resulting precipitate was dissolved in water-acetonitrile (50%:50%) and lyophilised.

Mono-sCy5-(2*S*,7*S*)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*S,S*)-14)

According to the general method for fluorescent labelling described above, (*S,S*)-1 (10 mg) was treated with sCy5-OH (0.7 eq.). After purification, (*S,S*)-14 was obtained as a fluffy blue powder (1.3 mg). HPLC RT 12.38 min. ESI-MS: 782.70 (M+3H)³⁺.

Mono-sCy5-(2*R*,7*R*)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*R,R*)-14)

According to the general method for fluorescent labelling described above, (*R,R*)-1, (5.9 mg) was treated with sCy5-OH (0.7 eq.). After purification, (*R,R*)-14 was obtained as a fluffy blue powder (1.2 mg). HPLC RT 12.36 min. ESI-MS: 782.75 (M+3H)³⁺.

Mono-RhB-(2*S*,7*S*)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*S,S*)-15)

According to the general method for fluorescent labelling described above, (*S,S*)-1, (10 mg) was treated with RhB-OH (0.7 eq.). After purification, (*S,S*)-15 was obtained as a fluffy magenta powder (0.5 mg). HPLC RT 13.37 min. ESI-MS: 767.40 (M+3H)³⁺.

Mono-RhB-(2*S*,7*S*)-Diaminooct-4-enedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*S,S*)-16)

According to the general method for fluorescent labelling described above, (*S,S*)-9, (10 mg) was treated with RhB-OH (0.7 eq.). After purification, (*S,S*)-16 was obtained as a fluffy magenta powder (1.2 mg). HPLC RT 13.36 min. ESI-MS: 766.65 (M+3H)³⁺.

Mono-RhB-(2*R*,7*R*)-Diaminooct-4-enedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((*R,R*)-16)

1
2
3 According to the general method for fluorescent labelling described above, (*R,R*)-**9**, (10 mg)
4
5 was treated with RhB-OH (0.7 eq.). After purification, (*R,R*)-**16** was obtained as a fluffy magenta
6
7 powder (1.4 mg). HPLC RT 13.26 min. ESI-MS: 766.70 (M+3H)³⁺.
8

9 10 **Cell culture**

11 HEK293T and 293TR cells (Invitrogen) were cultured in Dulbecco's modified Eagle's
12
13 medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum, and passaged
14
15 when confluent by trypsinisation (0.25% w/v in Versene). Mixed population 293TR cell lines
16
17 inducibly expressing Y receptors tagged with C-terminal GFP, and dual stable HEK293 cell
18
19 lines expressing Y receptor-Yc and β -arrestin2-Yn (where Yc and Yn are complementary
20
21 fragments of YFP) are as previously reported.^{35, 39, 40}
22
23

24 25 **Y₄R competition binding and imaging assays**

26
27 293TR Y₄-GFP or Y₁-GFP cells were seeded at 20,000 cells / well in poly-D-lysine coated
28
29 96-well imaging plates (Greiner 655090), treated as required with 1 μ g/ml tetracycline for
30
31 18-21 h and then used in experiments at confluence. Incubations were performed in HEPES-
32
33 buffered saline solution (HBSS) including 0.1% BSA, the permeable nuclear dye H33342 (2
34
35 μ g/ml, Sigma) and varying concentrations of competitor ligands (10^{-10} M to 10^{-5} M) for 2
36
37 min, prior to the addition of fluorescent ligand at the concentration indicated. After 30 min at
38
39 37°C the media was replaced with HBSS / 0.1% BSA and plates were immediately imaged (2
40
41 sites / well) on an IX Ultra confocal platereader (Molecular Devices, Sunnyvale CA, U.S.A.)
42
43 using laser excitation / emission filter settings appropriate for H33342 (DAPI), Y receptor-
44
45 GFP (FITC), and sCy5-labelled peptides. Bound ligand fluorescence was quantified by
46
47 granularity analysis (2-3 μ m diameter granules; MetaXpress 5.3, Molecular Devices), and
48
49 normalised to positive (totals 100 %) and negative (0%, in presence of 100 nM PP) controls.
50
51 pIC₅₀ values were then determined from the pooled data using GraphPad Prism v6 (GraphPad
52
53 software, San Diego, CA).
54
55
56
57
58
59
60

Y₄R-β-arrestin recruitment assays

Bimolecular fluorescence complementation (BiFC) based detection of Y receptor-β-arrestin2 association was performed as described previously.^{39, 40} The Y₄R arrestin BiFC cell lines were seeded at 40,000 cells / well onto poly-D-lysine coated Greiner 655090 imaging plates, and experiments performed 24 h later. Stimulation with human PP (Bachem, St. Helens, U.K.) or other ligands was performed in HBSS / 0.1% BSA (10⁻¹⁰ M-10⁻⁶ M, duplicate wells) for 60 min at 37°C. Incubations were terminated by fixation with 3% paraformaldehyde in phosphate buffered saline (PBS, 10 min at 21°C), the cells were washed once with PBS and the cell nuclei were stained for 15 min with H33342 (2 μg ml⁻¹ in PBS, Sigma). H33342 was then removed by a final PBS wash. Images (4 central sites / well) were acquired automatically on the IX Ultra confocal platerreader, using 405 nm / 488 nm laser lines for H33342 and complemented YFP excitation respectively.

A granularity algorithm (MetaXpress 5.3) identified internal fluorescent compartments within these images of at least 3 μm diameter (range set to 3-1 μm), on the basis of granule intensity thresholds set with reference to the vehicle or 100 nM PP plate controls. The response for each data point was quantified as mean granule average intensity / cell, normalised to the reference agonist response. Concentration response curves were fitted to the pooled data by non-linear least squares regression (GraphPad Prism), yielding estimates of agonist potency as pEC₅₀ and maximum response (R_{max}).

Corresponding Author Information

Associate Professor Philip E. Thompson

Tel: +61 3 99039672

Email: philip.thompson@monash.edu

Acknowledgements

1
2
3 ML was supported by an Australian Post-graduate Award scholarship. RRR was supported
4
5 by the Nottingham-Monash PhD program.
6

7
8 *Supporting Information Available*

9
10 Experimental data relating to protected amino acid synthesis, chiral chromatography of
11
12 (2*S*,7*S*)-**5** and (2*R*,7*R*)-**5**, HPLC spectra for all peptides and fluorescence spectra of (*R,R*)-**14**.
13

14 This material is available free of charge via the Internet at <http://pubs.acs.org>.
15

16
17 *Abbreviations Used*

18
19 BiFC Bimolecular fluorescence complementation
20
21 DCM dichloromethane
22
23 DIPEA N,N-diisopropylethylamine
24
25 DMAP 4-dimethylaminopyridine
26
27 DMF N,N-dimethylformamide
28
29 EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
30
31 EDT 1,2-ethanedithiol
32
33 EtOAc ethyl acetate
34
35 GFP green fluorescent protein
36
37 HCTU *O*-(6-chlorobenzotriazol-1-yl)-*N,N,N,N*-tetramethyluronium
38
39 hexafluorophosphate
40
41 MeOH methanol
42
43 NMM N-methylmorpholine
44
45 Pd/C palladium on activated carbon
46
47 PyClock (6-Chlorobenzotriazol-1-yloxy)tripyrrolidinophosphonium
48
49 hexafluorophosphate
50
51
52
53
54
55
56
57
58
59
60

References

1. Tatemoto, K. Neuropeptide Y: complete amino acid sequence of the brain peptide. *Proc. Natl. Acad. Sci. U.S.A.* **1982**, *79*, 5485-5489.
2. Tatemoto, K.; Mutt, V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. *Nature* **1980**, *285*, 417-418.
3. Hoffmann, J. A.; Chance, R. E. Crystallization of bovine pancreatic polypeptide. *Biochem. Biophys. Res. Commun.* **1983**, *116*, 830-835.
4. Blomqvist, A. G.; Herzog, H. Y-receptor subtypes—how many more? *Trends in Neurosciences* **1997**, *20*, 294-298.
5. Balasubramaniam, A. Neuropeptide Y (NPY) family of hormones: progress in the development of receptor selective agonists and antagonists. *Curr. Pharm. Des.* **2003**, *9*, 1165-1175.
6. Edelsbrunner, M. E.; Painsipp, E.; Herzog, H.; Holzer, P. Evidence from knockout mice for distinct implications of neuropeptide-Y Y₂ and Y₄ receptors in the circadian control of locomotion, exploration, water and food intake. *Neuropeptides* **2009**, *43*, 491-497.
7. Uhe, A. M.; Szmukler, G. I.; Collier, G. R.; Hansky, J.; O'Dea, K.; Young, G. P. Potential regulators of feeding behavior in anorexia nervosa. *Am. J. Clin. Nutr.* **1992**, *55*, 28-32.
8. Marco, J.; Zulueta, M. A.; Correas, I.; Villanueva, M. L. Reduced pancreatic polypeptide secretion in obese subjects. *J. Clin. Endocrinol. Metab.* **1980**, *50*, 744-747.
9. Lassmann, V.; Vague, P.; Vialettes, B.; Simon, M.-C. Low plasma levels of pancreatic polypeptide in obesity. *Diabetes* **1980**, *29*, 428-430.
10. Berlicki, Ł.; Kaske, M.; Gutiérrez-Abad, R.; Bernhardt, G.; Illa, O.; Ortuño, R. M.; Cabrele, C.; Buschauer, A.; Reiser, O. Replacement of Thr³² and Gln³⁴ in the C-terminal neuropeptide Y fragment 25–36 by *cis*-cyclobutane and *cis*-cyclopentane β-amino acids shifts selectivity toward the Y₄ receptor. *J. Med. Chem.* **2013**, *56*, 8422-8431.
11. Leban, J. J.; Heyer, D.; Landavazo, A.; Matthews, J.; Aulabaugh, A.; Daniels, A. J. Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y₂-type receptors and potent functional antagonism at the Y₁-type receptor. *J. Med. Chem.* **1995**, *38*, 1150-1157.
12. Balasubramaniam, A.; Dhawan, V. C.; Mullins, D. E.; Chance, W. T.; Sheriff, S.; Guzzi, M.; Prabhakaran, M.; Parker, E. M. Highly selective and potent neuropeptide Y (NPY) Y₁ receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH₂ (BW1911U90). *J. Med. Chem.* **2001**, *44*, 1479-1482.
13. Parker, E. M.; Babij, C. K.; Balasubramaniam, A.; Burrier, R. E.; Guzzi, M.; Hamud, F.; Gitali, M.; Rudinski, M. S.; Tao, Z.; Tice, M.; Xia, L.; Mullins, D. E.; Salisbury, B. G. GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y₁ receptor antagonists and neuropeptide Y Y₄ receptor agonists. *Eur. J. Pharmacol.* **1998**, *349*, 97-105.
14. Daniels, A. J.; Matthews, J. E.; Slepatis, R. J.; Jansen, M.; Viveros, O. H.; Tadepalli, A.; Harrington, W.; Heyer, D.; Landavazo, A.; Leban, J. J. High-affinity neuropeptide Y receptor antagonists. *Proc. Natl. Acad. Sci.* **1995**, *92*, 9067-9071.
15. Gehlert, D. R.; Schober, D. A.; Beavers, L.; Gadski, R.; Hoffman, J. A.; Smiley, D. L.; Chance, R. E.; Lundell, I.; Larhammar, D. Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. *Mol. Pharmacol.* **1996**, *50*, 112-118.

- 1
2
3 16. Matthews, J. E.; Jansen, M.; Lysterly, D.; Cox, R.; Chen, W.-J.; Koller, K. J.; Daniels, A. J. Pharmacological characterization and selectivity of the NPY antagonist GR231118 (1229U91) for different NPY receptors. *Regul. Pept.* **1997**, *72*, 113-119.
- 4
5
6 17. Schober, D. A.; Gackenheimer, S. L.; Heiman, M. L.; Gehlert, D. R. Pharmacological characterization of ¹²⁵I-1229U91 binding to Y₁ and Y₄ neuropeptide Y/peptide YY receptors. *J. Pharmacol. Exp. Ther.* **2000**, *293*, 275-280.
- 7
8
9 18. Balasubramaniam, A.; Mullins, D. E.; Lin, S.; Zhai, W.; Tao, Z.; Dhawan, V. C.; Guzzi, M.; Knittel, J. J.; Slack, K.; Herzog, H.; Parker, E. M. Neuropeptide Y (NPY) Y₄ receptor selective agonists based on NPY(32-36): development of an anorectic Y₄ receptor selective agonist with picomolar affinity. *J. Med. Chem.* **2006**, *49*, 2661-2665.
- 10
11
12 19. Li, J.-B.; Asakawa, A.; Terashi, M.; Cheng, K.; Chaolu, H.; Zoshiki, T.; Ushikai, M.; Sheriff, S.; Balasubramaniam, A.; Inui, A. Regulatory effects of Y₄ receptor agonist (BVD-74D) on food intake. *Peptides* **2010**, *31*, 1706-1710.
- 13
14
15 20. Robinson, A. J.; Elaridi, J.; Van Lierop, B. J.; Mujcinovic, S.; Jackson, W. R. Microwave-assisted RCM for the synthesis of carbocyclic peptides. *J. Pept. Sci.* **2007**, *13*, 280-285.
- 16
17
18 21. Van Lierop, B. J.; Bornschein, C.; Jackson, W. R.; Robinson, A. J. Ring-closing metathesis in peptides - the sting is in the tail! *Aust. J. Chem.* **2011**, *64*, 806-811.
- 19
20
21 22. Elaridi, J.; Patel, J.; Jackson, W. R.; Robinson, A. J. Controlled synthesis of (S,S)-2,7-diaminosuberic acid: a method for regioselective construction of dicarba analogues of multicystine-containing peptides. *J. Org. Chem.* **2006**, *71*, 7538-7545.
- 22
23
24 23. Passarella, D.; Peretto, B.; Blasco y Yepes, R.; Cappelletti, G.; Cartelli, D.; Ronchi, C.; Snaith, J.; Fontana, G.; Danieli, B.; Borlak, J. Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates. *Eur. J. Med. Chem.* **2010**, *45*, 219-226.
- 25
26
27 24. Nolen, E. G.; Fedorka, C. J.; Blicher, B. Synthesis of orthogonally protected S,S-2,6-diaminopimelic acid via olefin cross-metathesis. *Synth. Commun.* **2006**, *36*, 1707-1713.
- 28
29
30 25. Ward, M. D.; Zhu, Z. Compounds as L-cystine crystallization inhibitors and uses thereof. US 2012/0316236, Dec.13, 2012, 2012.
- 31
32
33 26. Hiebl, J.; Blanka, M.; Guttman, A.; Kollmann, H.; Leitner, K.; Mayrhofer, G.; Rovenszky, F.; Winkler, K. A detailed investigation of the preparation of 2,7-diaminosuberic acid and 2,5-diaminoadipic acid derivatives using Kolbe electrolysis. *Tetrahedron* **1998**, *54*, 2059-2074.
- 34
35
36 27. Williams, R. M.; Liu, J. Asymmetric synthesis of differentially protected 2,7-diaminosuberic acid, a ring-closure metathesis approach. *J. Org. Chem.* **1998**, *63*, 2130-2132.
- 37
38
39 28. Aguilera, B.; Wolf, L. B.; Nieczypor, P.; Rutjes, F. P. J. T.; Overkleeft, H. S.; van Hest, J. C. M.; Schoemaker, H. E.; Wang, B.; Mol, J. C.; Furstner, A.; Overhand, M.; van der Marel, G. A.; van Boom, J. H. Synthesis of diaminosuberic acid derivatives via ring-closing alkyne metathesis. *J. Org. Chem.* **2001**, *66*, 3584-3589.
- 40
41
42 29. Hiebl, J.; Kollmann, H.; Rovenszky, F.; Winkler, K. One step synthesis of orthogonally protected diaminodicarboxylic acids by mixed kolbe electrolysis. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 2963-2966.
- 43
44
45 30. Cabrele, C.; Langer, M.; Beck-Sickinger, A. G. Amino acid side chain attachment approach and its application to the synthesis of tyrosine-containing cyclic peptides. *J. Org. Chem.* **1999**, *64*, 4353-4361.
- 46
47
48 31. Rizzi, L.; Cendic, K.; Vaiana, N.; Romeo, S. Alcohols immobilization onto 2-chlorotriylchloride resin under microwave irradiation. *Tetrahedron Lett.* **2011**, *52*, 2808-2811.
- 49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 32. Adamson, J. G.; Blaskovich, M. A.; Groenevelt, H.; Lajoie, G. A. Simple and
4 convenient synthesis of tert-butyl ethers of Fmoc-serine, Fmoc-threonine, and Fmoc-
5 tyrosine. *J. Org. Chem.* **1991**, *56*, 3447-3449.
- 6 33. Combs, A. P.; Yue, E. W.; Bower, M.; Ala, P. J.; Wayland, B.; Douty, B.; Takvorian, A.;
7 Polam, P.; Wasserman, Z.; Zhu, W.; Crawley, M. L.; Pruitt, J.; Sparks, R.; Glass, B.; Modi, D.;
8 McLaughlin, E.; Bostrom, L.; Li, M.; Galya, L.; Blom, K.; Hillman, M.; Gonneville, L.; Reid, B.
9 G.; Wei, M.; Becker-Pasha, M.; Klabe, R.; Huber, R.; Li, Y.; Hollis, G.; Burn, T. C.; Wynn, R.;
10 Liu, P.; Metcalf, B. Structure-based design and discovery of protein tyrosine phosphatase
11 inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine
12 mimetics. *J. Med. Chem.* **2005**, *48*, 6544-6548.
- 13 34. Nguyen, T.; Francis, M. B. Practical synthetic route to functionalized rhodamine
14 dyes. *Org. Lett.* **2003**, *5*, 3245-3248.
- 15 35. Mountford, S. J.; Liu, M.; Zhang, L.; Groenen, M.; Herzog, H.; Holliday, N. D.;
16 Thompson, P. E. Synthetic routes to the Neuropeptide Y Y₁ receptor antagonist 1229U91
17 and related analogues for SAR studies and cell-based imaging. *Org. Biomol. Chem.* **2014**,
18 *12*, 3271-3281.
- 19 36. Stoddart, Leigh A.; Vernall, Andrea J.; Denman, Jessica L.; Briddon, Stephen J.;
20 Kellam, B.; Hill, Stephen J. Fragment screening at adenosine-A₃ receptors in living cells
21 using a fluorescence-based binding assay. *Chem. Biol.* **2012**, *19*, 1105-1115.
- 22 37. Liu, M. J.; Mountford, S. J.; Zhang, L.; Lee, I. C.; Herzog, H.; Thompson, P. E.
23 Synthesis of BVD15 peptide analogues as models for radioligands in tumour imaging.
24 *Int. J. Pept. Res. Ther.* **2013**, *19*, 33-41.
- 25 38. Michel, M. C.; Beck-Sickinger, A.; Cox, H.; Doods, H. N.; Herzog, H.; Larhammar, D.;
26 Quirion, R.; Schwartz, T.; Westfall, T. XVI. International union of pharmacology
27 recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic
28 polypeptide receptors. *Pharmacol. Rev.* **1998**, *50*, 143-150.
- 29 39. Kilpatrick, L. E.; Briddon, S. J.; Hill, S. J.; Holliday, N. D. Quantitative analysis of
30 neuropeptide Y receptor association with β -arrestin2 measured by bimolecular
31 fluorescence complementation. *Br. J. Pharmacol.* **2010**, *160*, 892-906.
- 32 40. Kilpatrick, L. E.; Briddon, S. J.; Holliday, N. D. Fluorescence correlation
33 spectroscopy, combined with bimolecular fluorescence complementation, reveals the
34 effects of β -arrestin complexes and endocytic targeting on the membrane mobility of
35 neuropeptide Y receptors. *Biochim. Biophys. Acta.* **2012**, *1823*, 1068-1081.
- 36 41. Stott, L. A.; Hall, D. A.; Holliday, N. D. Unravelling intrinsic efficacy and ligand bias
37 at G protein coupled receptors: A practical guide to assessing functional data. *Biochem.*
38 *Pharmacol.* **2016**, *101*, 1-12.
- 39 42. Pedragosa-Badia, X.; Sliwoski, G. R.; Dong Nguyen, E.; Lindner, D.; Stichel, J.;
40 Kaufmann, K. W.; Meiler, J.; Beck-Sickinger, A. G. Pancreatic polypeptide is recognized by
41 two hydrophobic domains of the human Y₄ receptor binding pocket. *J. Bio. Chem.* **2014**,
42 *289*, 5846-5859.
- 43 43. Baker, J. G.; Middleton, R.; Adams, L.; May, L. T.; Briddon, S. J.; Kellam, B.; Hill, S. J.
44 Influence of fluorophore and linker composition on the pharmacology of fluorescent
45 adenosine A1 receptor ligands. *Br. J. Pharmacol.* **2010**, *159*, 772-786.
- 46 44. Briddon, S.; Kellam, B.; Hill, S. Design and use of fluorescent ligands to study
47 ligand-receptor interactions in single living cells. In *Receptor Signal Transduction*
48 *Protocols*, Willars, G. B.; Challiss, R. A. J., Eds. Humana Press: 2011; Vol. 746, pp 211-236.
- 49
50
51
52
53
54
55
56
57
58
59
60

TABLE OF CONTENTS GRAPHIC

